Trial Profile
HDAC inhibitor vorinostat in resistant BRAF V600 mutated advanced melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Malignant melanoma
- Focus Proof of concept; Therapeutic Use
- 22 Jun 2016 New trial record